相似文献
1
The importance of antiandrogen in prostate cancer treatment.
Ann Transl Med. 2019 Dec;7(Suppl 8):S362. doi: 10.21037/atm.2019.09.53.
2
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17.
3
Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model.
Jpn J Clin Oncol. 2014 Mar;44(3):263-9. doi: 10.1093/jjco/hyt230. Epub 2014 Feb 9.
4
Antiandrogen withdrawal in the treatment of hormone-relapsed prostate cancer: single institutional experience.
Eur Urol. 2001 Jan;39 Suppl 2:6-10. doi: 10.1159/000052550.
5
Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.
Drug Saf. 2000 Nov;23(5):381-90. doi: 10.2165/00002018-200023050-00003.
6
Predictors of poor response to secondary alternative antiandrogen therapy with flutamide in metastatic castration-resistant prostate cancer.
Jpn J Clin Oncol. 2016 Nov 1;46(11):1042-1046. doi: 10.1093/jjco/hyw110.
7
Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate.
Eur Urol. 1998;33(6):567-71. doi: 10.1159/000019657.
8
Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate.
Urology. 1995 Apr;45(4):700-4; discussion 704-5. doi: 10.1016/S0090-4295(99)80070-3.
9
Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Oncogene. 2005 Apr 7;24(15):2474-82. doi: 10.1038/sj.onc.1208490.
10
Increased expression of activated endothelial nitric oxide synthase contributes to antiandrogen resistance in prostate cancer cells by suppressing androgen receptor transactivation.
Cancer Lett. 2013 Jan 1;328(1):83-94. doi: 10.1016/j.canlet.2012.09.006. Epub 2012 Sep 18.
引用本文的文献
1
Sexual dimorphism in colorectal cancer: molecular mechanisms and treatment strategies.
Biol Sex Differ. 2024 Jun 12;15(1):48. doi: 10.1186/s13293-024-00623-1.
2
Systematic transcriptional analysis of human cell lines for gene expression landscape and tumor representation.
Nat Commun. 2023 Sep 5;14(1):5417. doi: 10.1038/s41467-023-41132-w.
3
Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo.
J Exp Clin Cancer Res. 2023 May 20;42(1):128. doi: 10.1186/s13046-023-02695-0.
4
STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide.
Mol Med Rep. 2023 Feb;27(2). doi: 10.3892/mmr.2023.12939. Epub 2023 Jan 20.
5
Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients.
Viruses. 2022 Dec 7;14(12):2728. doi: 10.3390/v14122728.
6
TLX, an Orphan Nuclear Receptor With Emerging Roles in Physiology and Disease.
Endocrinology. 2021 Nov 1;162(11). doi: 10.1210/endocr/bqab184.
本文引用的文献
1
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.
2
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31.
3
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
4
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3.
5
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.
6
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.
7
Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
J Urol. 2018 Jan;199(1):147-154. doi: 10.1016/j.juro.2017.08.080. Epub 2017 Aug 19.
8
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24.
9
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4.
10
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Eur Urol. 2016 Dec;70(6):963-970. doi: 10.1016/j.eururo.2016.04.023. Epub 2016 May 6.
Zotero 插件